Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on May 05, 2023 12:20pm
99 Views
Post# 35433204

RE:RE:RE:RE:RE:RE:Addressable market

RE:RE:RE:RE:RE:RE:Addressable market A patient cannot inject himself an intra-muscular drug. I had IM injections every month for the last seven years and it had to be performed by a nurse, either at home, or in a clinic. I recently switched to another injectable drug which is given by what they call deep subcutaneous injection. The injection site is on the side of the hip/buttock. I was given the choice to learn to do it myself or to have a nurse coming to my home every month to do it. I chose the nurse. I don't fear injections, but given the choice, the nurse was the better option. That being said, deep subcutaneous is much more patient friendly than IM, it's almost painless, while with IM you ended up with a little bruise like pain for 2 to 3 days.


SPCEO1 wrote: Yes, I believe that is correct. And it could prove very helpful to sales but it is still hard to beat a pill even then. That data reported yesterday, however, if THTX is able to communicate it effectively to doctors, may be enough for patients to be willing to take the Trogarzo shot over competing pills. But don't expect immediate results on the Trogarzo sales front as it will take time for that data to be spread to doctors and my guess is patients are still likely to opt for pills unless their doctor makes a really convincing case to them. Some doctors will and some won't. So, it should help Trogarzo sales but time will tell by how much.

LouisW wrote: Your "simple at home" comment really interests me. Are you saying IM can be performed at home by themself? Patients no need to go to hospital?




<< Previous
Bullboard Posts
Next >>